IDF21-0087 Metabolic interventions for diabetes treatment are associated with gut microbiota changes: a systematic review

Maraschin, C. Krummenauer; Bock, M.P.; Leivas, Gabriel; Martins, F.A.; Ramalho, Renan da Silva; Teló, H.G.; Schaan, D.B.

doi:10.1016/j.diabres.2022.109460

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…139 BSH activity is widely reported to be present in food-grade probiotics such as Lactobacillus, Lactococcus and Bifidobacterium. 140 Lactobacillus plantarum has been shown to deconjugate bile acids in the host intestinal lumen via the production of bile acid hydrochloride. 141,142 Others like Lactobacillus acidophilus have been shown…”

Section: Discussionmentioning

confidence: 99%

Microbiome‐modulating nutraceuticals ameliorate dyslipidemia in type 2 diabetes: A systematic review, meta‐analysis, and meta‐regression of clinical trials

Kaul

Paul

Harfouche

et al. 2023

Diabetes Metabolism Res

View full text Add to dashboard Cite

AimsType 2 Diabetes is intrinsically linked to cardiovascular disease (CVD) via diabetic dyslipidemia, both of which remain global health concerns with annually increasing prevalence. Given the established links between gut microbiome dysbiosis and metabolic diseases, its modulation is an attractive target to ameliorate metabolic imbalances in such patients. There is a need to quantitively summarise, analyse, and describe future directions in this field.MethodsWe conducted a systematic review, meta‐analysis, and meta‐regression following searches in major scientific databases for clinical trials investigating the effect of pro/pre/synbiotics on lipid profile published until April 2022. Data were pooled using random‐effects meta‐analysis and reported as mean differences with 95% confidence intervals (CIs). PROSPERO No. CRD42022348525.ResultsData from 47 trial comparisons across 42 studies (n = 2692) revealed that, compared to placebo/control groups, the administration of pro/pre/synbiotics was associated with statistically significant changes in total cholesterol (−9.97 mg/dL [95% CI: −15.08; −4.87], p < 0.0001), low‐density lipoprotein (−6.29 mg/dL [95% CI: −9.25; −3.33], p < 0.0001), high‐density lipoprotein (+3.21 mg/dL [95% CI: 2.20; 4.22], p < 0.0001), very‐low‐density lipoprotein (−4.52 mg/dL [95% CI: −6.36; −2.67], p < 0.0001) and triglyceride (−22.93 mg/dL [95% CI: −33.99; −11.87], p < 0.001). These results are influenced by patient characteristics such as age or baseline BMI, and intervention characteristics such as dosage and duration.ConclusionsOur study shows that adjunct supplementation with a subset of pro/pre/synbiotics ameliorates dyslipidemia in diabetic individuals and has the potential to reduce CVD risk. However, widespread inter‐study heterogeneity and the presence of several unknown confounders limit their adoption in clinical practice; future trials should be designed with these in mind.

show abstract

Section: Discussionmentioning

confidence: 99%

Microbiome‐modulating nutraceuticals ameliorate dyslipidemia in type 2 diabetes: A systematic review, meta‐analysis, and meta‐regression of clinical trials

Kaul

Paul

Harfouche

et al. 2023

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…Prebiotics can be selectively absorbed and transformed into helpful health compounds by the host flora. Several studies have found that probiotics, prebiotics, and other microbial alteration therapies have an influence on appetite and body weight ( 3 ). The addition of probiotics to replenish reduced taxa in T2DM therapy may enhance gut metabolic activities (e.g., immunomodulation, SCFAs synthesis, and bile acid metabolism regulation) ( 52 ).…”

Section: Potential Mechanism Of Astragali Radix In the Treatment Of T2dmmentioning

confidence: 99%

“…T2DM is strongly linked to the intestinal microbiota, according to research. The main aspects are mainly in the immune system, energy metabolism, intestinal screen function, intestinal barrier function ( 3 ). Numerous studies have shown that the occurrence of T2DM is closely related to the intestinal microbiota, which is increasingly recognized as a key factor in the development of T2DM.…”

Section: Introductionmentioning

confidence: 99%

“…These functions are considered to be the original application of the herb in immunomodulation ( 10 ). And the important role of Astragali Radix in modulating immune function in humans and experimental animals is inextricably linked to the intestinal microflora and intestinal barrier function ( 3 , 7 ). A variety of chemical substances have been isolated and identified from Astragali Radix, including saponins, flavonoids and polysaccharides.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review

Su,

Tang,

Tang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Diabetes is a significant chronic endocrine/metabolism disorder that can result in a number of life-threatening consequences. According to research, the gut microbiota is strongly linked to the development of diabetes, making it a viable target for diabetes treatment. The intestinal microbiota affects intestinal barrier function, organism immunity, and thus glucose metabolism and lipid metabolism. According to research, a disruption in the intestinal microbiota causes a decrease in short-chain fatty acids (SCFAs), alters the metabolism of bile acids (BAs), branched-chain amino acids (BCAAs), lipopolysaccharide (LPS), and endotoxin secretion, resulting in insulin resistance, chronic inflammation, and the progression to type 2 diabetes mellitus (T2DM). Astragali Radix is a medicinal herb of the same genus as food that has been extensively researched for treating diabetes mellitus with promising results in recent years. Polysaccharides, saponins, flavonoids, and other components are important. Among them, Astragaloside has a role in protecting the cellular integrity of the pancreas and liver, can leading to alleviation of insulin resistance and reducing blood glucose and triglyceride (TC) levels; The primary impact of Astragalus polysaccharides (APS) on diabetes is a decrease in insulin resistance, encouragement of islet cell proliferation, and suppression of islet β cell death; Astragali Radix flavonoids are known to enhance immunity, anti-inflammatory, regulate glucose metabolism and control the progression of diabetes. This study summarizes recent studies on Astragali Radix and its group formulations in the treatment of type 2 diabetes mellitus by modulating the intestinal microbiota.

show abstract

IDF21-0087 Metabolic interventions for diabetes treatment are associated with gut microbiota changes: a systematic review

Cited by 2 publications

References 0 publications

Microbiome‐modulating nutraceuticals ameliorate dyslipidemia in type 2 diabetes: A systematic review, meta‐analysis, and meta‐regression of clinical trials

Microbiome‐modulating nutraceuticals ameliorate dyslipidemia in type 2 diabetes: A systematic review, meta‐analysis, and meta‐regression of clinical trials

Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review

Contact Info

Product

Resources

About